Are Wall Street Analysts Predicting Agilent Technologies Stock Will Climb or Sink?
/Agilent%20Technologies%20Inc_%20phone%20and%20logo-by%20IgorGolovniov%20via%20Shutterstock.jpg)
Agilent Technologies, Inc. (A), headquartered in Santa Clara, California, provides application focused solutions to the life sciences, diagnostics, and applied chemical markets. Valued at $32.3 billion by market cap, the company offers electronic and bio-analytical measurement, semiconductor, and board testing.
Shares of this global leader in analytical and clinical laboratory technologies have considerably underperformed the broader market over the past year. A has declined 26.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 11.9%. In 2025, A stock is down 15.5%, compared to the SPX’s 1% rise on a YTD basis.
Narrowing the focus, A’s underperformance is also apparent compared to the Robo Global Healthcare Technology and Innovation ETF (HTEC). The exchange-traded fund has fallen about 1.7% over the past year. Moreover, the ETF’s 4.2% dip on a YTD basis outshine the stock’s double-digit losses over the same time frame.
On Feb. 26, A reported its Q1 results, and its shares closed down more than 5% in the following trading session. Its adjusted EPS of $1.31 surpassed Wall Street expectations of $1.27. The company’s revenue was $1.68 billion, beating Wall Street forecasts of $1.67 billion. A expects full-year adjusted EPS in the range of $5.54 to $5.61, and expects revenue to be between $6.7 billion and $6.8 billion.
For the current fiscal year, ended in October, analysts expect A’s EPS to grow 4.7% to $5.54 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.
Among the 16 analysts covering A stock, the consensus is a “Moderate Buy.” That’s based on eight “Strong Buy” ratings, and eight “Holds.”
The configuration is consistent over the past three months.
On Apr. 21, Jefferies Financial Group Inc. (JEF) kept a “Hold” rating on A and lowered its price target to $116, implying a potential upside of 2.2% from current levels.
The mean price target of $139 represents a 22.5% premium to A’s current price levels. The Street-high price target of $165 suggests a notable upside potential of 45.4%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.